Compound Design by Fragment‐Linking

The linking together of two fragment compounds that bind to distinct protein sub‐sites can lead to a superadditivity of binding affinities, in which the binding free energy of the linked fragments exceeds the simple sum of the binding energies of individual fragments (linking coefficient E<1). However, a review of the literature shows that such events are relatively rare and, in the majority of the cases, linking coefficients are far from optimal being much greater than 1. It is critical to design a linker that does not disturb the original binding poses of each fragment in order to achieve successful linking. However, such an ideal linker is often difficult to design and even more difficult to actually synthesize. We suggest that the chance of achieving successful fragment linking can be significantly improved by choosing a fragment pair that consists of one fragment that binds by strong H‐bonds (or non‐classical equivalents) and a second fragment that is more tolerant of changes in binding mode (hydrophobic or vdW binders). We also propose that the fragment molecular orbital (FMO) calculations can be used to analyse the nature of the binding interactions of the fragment hits for the selection of fragments for evolution, merging and linking in order to optimize the chance of success.

[1]  Keiji Morokuma,et al.  Molecular Orbital Studies of Hydrogen Bonds. III. C=O···H–O Hydrogen Bond in H2CO···H2O and H2CO···2H2O , 1971 .

[2]  Kazuo Kitaura,et al.  A new energy decomposition scheme for molecular interactions within the Hartree‐Fock approximation , 1976 .

[3]  Hideaki Umeyama,et al.  The origin of hydrogen bonding. An energy decomposition study , 1977 .

[4]  W. Jencks,et al.  On the attribution and additivity of binding energies. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[6]  D A Dougherty,et al.  Cation-pi interactions in aromatics of biological and medicinal interest: electrostatic potential surfaces as a useful qualitative guide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Jean M. Severin,et al.  Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR , 1997 .

[8]  P. Hajduk,et al.  Stromelysin Inhibitors Designed from Weakly Bound Fragments: Effects of Linking and Cooperativity , 1997 .

[9]  D. A. Dougherty,et al.  Cation-π interactions in structural biology , 1999 .

[10]  K. Kitaura,et al.  Fragment molecular orbital method: an approximate computational method for large molecules , 1999 .

[11]  Dustin J Maly,et al.  Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Harren Jhoti,et al.  High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.

[13]  R. Griffey,et al.  SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. , 2002, Journal of medicinal chemistry.

[14]  Marcel L. Verdonk,et al.  The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..

[15]  Gang Liu,et al.  Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. , 2003, Journal of medicinal chemistry.

[16]  Gang Liu,et al.  Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. , 2003, Journal of the American Chemical Society.

[17]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[18]  Jeffrey W. Bode,et al.  Reactor ChemAxon Ltd., Maramaros koz 2/a, Budapest, 1037 Hungary. www.chemaxon.com. Contact ChemAxon for pricing information. , 2004 .

[19]  末永 正彦,et al.  PC GAMESSのための新しい計算化学統合環境 Facio の開発 , 2005 .

[20]  Gianni Chessari,et al.  Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.

[21]  Christopher W. Murray,et al.  Entropic Consequences of Linking Ligands , 2006 .

[22]  P. Hajduk,et al.  Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. , 2006, Journal of medicinal chemistry.

[23]  Lisa M. Shewchuk,et al.  Crystallization of protein–ligand complexes , 2006, Acta crystallographica. Section D, Biological crystallography.

[24]  T. Hesterkamp,et al.  Fragment based drug discovery using fluorescence correlation: spectroscopy techniques: challenges and solutions. , 2007, Current topics in medicinal chemistry.

[25]  G. Siegal,et al.  Fragment‐Based Synthesis and SAR of Modified FKBP Ligands: Influence of Different Linking on Binding Affinity , 2007, ChemMedChem.

[26]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[27]  T Neumann,et al.  SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.

[28]  Kazuo Kitaura,et al.  Extending the power of quantum chemistry to large systems with the fragment molecular orbital method. , 2007, The journal of physical chemistry. A.

[29]  Kazuo Kitaura,et al.  Pair interaction energy decomposition analysis , 2007, J. Comput. Chem..

[30]  Edward R Zartler,et al.  Practical aspects of NMR-based fragment discovery. , 2007, Current topics in medicinal chemistry.

[31]  Alexander A Alex,et al.  Fragment-based drug discovery: what has it achieved so far? , 2007, Current topics in medicinal chemistry.

[32]  Tomonaga Ozawa,et al.  The importance of CH/pi hydrogen bonds in rational drug design: An ab initio fragment molecular orbital study to leukocyte-specific protein tyrosine (LCK) kinase. , 2008, Bioorganic & medicinal chemistry.

[33]  Masahiko Suenaga,et al.  Development of GUI for GAMESS / FMO Calculation , 2008 .

[34]  E. Freire Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.

[35]  Mark Whittaker,et al.  Fragment-based activity space: smaller is better. , 2008, Current opinion in chemical biology.

[36]  Tjelvar S. G. Olsson,et al.  The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. , 2008, Journal of molecular biology.

[37]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[38]  Chris Abell,et al.  Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. , 2009, Angewandte Chemie.

[39]  A. Alex,et al.  Thermodynamic Optimisation in Drug Discovery: A Case Study using Carbonic Anhydrase Inhibitors , 2009, ChemMedChem.

[40]  Yoshihisa Inoue,et al.  Cl–π Interactions in Protein–Ligand Complexes , 2009 .

[41]  L. Mario Amzel,et al.  Impact of linker strain and flexibility in the design of a fragment-based inhibitor , 2009, Nature chemical biology.

[42]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[43]  Claudio Luchinat,et al.  Entropic contribution to the linking coefficient in fragment based drug design: a case study. , 2010, Journal of medicinal chemistry.

[44]  Thomas Hesterkamp,et al.  Fragments: past, present and future. , 2010, Drug discovery today. Technologies.

[45]  György G Ferenczy,et al.  Thermodynamics guided lead discovery and optimization. , 2010, Drug discovery today.

[46]  Mark Whittaker,et al.  Discovery of a Novel Hsp90 Inhibitor by Fragment Linking , 2010, ChemMedChem.

[47]  Amit Choudhary,et al.  n→π* Interactions in Proteins , 2010, Nature chemical biology.

[48]  M. Krohn,et al.  Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. , 2010, Journal of medicinal chemistry.

[49]  Chris Abell,et al.  Optimization of the interligand Overhauser effect for fragment linking: application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. , 2010, Journal of the American Chemical Society.